11/18/2014 2:00:00 AM
KineMed, Inc. announced today that two Chronic Lymphocytic Leukemia (CLL) studies utilizing KineMed’s proprietary kinetic biomarker technology will be presented at the American Society of Hematology Annual Meeting taking place December 6-9, 2014 in San Francisco, California. KineMed’s CLL research collaborators, Jan A. Burger, MD, Ph.D., of the MD Anderson Cancer Center, and Elizabeth J. Murphy, MD, DPhil, from the University of California San Francisco Department of Medicine and representing the CLL Research Consortium investigators, will present the studies at the conference.
11/4/2014 2:00:00 AM
KineMed, Inc. announced today that it has been awarded a three-year grant by the Bill & Melinda Gates Foundation to apply its novel, proprietary non-invasive measurement of skeletal muscle mass to pre-term and full-term infants and young children. The Principal Investigator, William Evans, Ph.D., is head of the KineMed Division of Muscle and Health. The study will, for the first time, measure changes in skeletal muscle mass during one year of growth. The information from this project will provide new information to better assess the effects of nutritional status and other factors that result in the loss of muscle.
10/28/2014 1:00:00 AM
KineMed, Inc. and the U.S. Army Research Institute of Environmental Medicine’s (USARIEM) Military Nutrition Division announced today they are entering into a partnership to examine KineMed’s platform technology to assess skeletal muscle protein synthesis and muscle mass in Warfighters.
Marc Hellerstein, M.D., Ph.D., President and Chief Scientific Officer
talks about the power of Proteome Dynamics at the Personalized Medicine World Conference